General contact information for trials in the Maritimes:

Nova Scotia:

Current trials:


Recruiting location in the Maritimes:

  • Halifax – QEII Health Sciences Centre (contact: Erin Little, 902-473-3735)

ID Number: NCT02935634


Description: This is a Phase III pilot trial. The participants in this study will be patients with Gastroesophageal Junction adenocarcinoma. The researchers want to know if perioperative chemotherapy or preoperative chemoradiotherapy is more helpful. This is a pilot study, which means that it is quite small and the researchers are trying to figure out if it is feasible to conduct a larger trial to answer their question with more data. They will compare the survival of two groups to try and find a better treatment for Gastroesophageal Junction cancer:

  • Group 1: the perioperative chemotherapy group will receive 1 of 2 possible chemotherapy routines: epirubicin/cisplatin/fluorouracil (ECF) or fluorouracil/leucovorin/oxaliplatin/docetaxel (FLOT). The chemotherapy is given before and after surgery.
  • Group 2: the preoperative group will receive chemotherapy and radiation therapy before surgery only. The drugs they will receive are carboplatin and paclitaxel.


  • Carboplatin and paclitaxel work to stop cancer cells from dividing. In this trial, they are given along with radiation therapy to treat the cancer.
  • The ECF and FLOT chemotherapy routines both work to try and stop cancer cells from dividing properly. Both are already prescribed commonly in gastric/gastroesophageal cancer treatment.

Can I consider participating?

  • YES: tumor of the esophagus or gastroesophageal junction which does not extend too far into the stomach itself (no more than 2 cm), aged 18-75, tumor is less than 8 cm in length and 5 cm in diameter
  • NO: have already tried chemotherapy or radiation therapy for esophageal/gastroesophageal cancer, had a malignant cancer within the last 5 years


Recruiting location in the Maritimes:

ID Number: NCT02773524


Description: This study is looking to determine if regorafenib improves survival in patients with advanced gastro-oesophageal carcinoma.

A: Regorafenib

B: Placebo

Intervention: Regorafenib is a targeted chemotherapy drug that is a tyrosine kinase inhibitor. It slows down or stops the growth of cancer cells.

Can I consider participating?

  • YES: patients who have advanced (metastatic or locally recurrent) gastro-oesophageal carcinoma that has not responded to minimum of 2 lines of prior anti-cancer therapy
  • NO: patients who have malabsorption syndromes, poorly-controlled hypertension, significant active infection


ACTIVE, no longer recruiting:

  • Moncton, New Brunswick – Moncton Hospital, Horizon Health Network (contact: Mrudula Avileli, 506-857-5669)

ID Number: NCT03221426


Description:This study is looking at the drug pembrolizumab (MK-3745) and its effectiveness before and after surgery treatment for gastric and gastroesophageal junction (GEJ) adenocarcinoma. 

Group A: Pembrolizumab and Chemotherapy

Group B: Placebo and Chemotherapy

Group C: Pembrolizumab and FLOT (docetaxel, oxaliplatin, 5-fluorouracil, leucovorin)

Group D: Placebo and FLOT

Intervention:Pembrolizuma is a drug which helps the immune system cells to attack and get rid of cancer cells. It is an immunotherapy medication.  FLOT are combination chemotherapy drugs that attack the cancerous cells.

Can I consider participating?

  • YES: patients who have untreated localized gastric or GEJ adenocarcinoma
  • NO: patients who have infections, autoimmune disease, prior anti-cancer therapy